Carisma Therapeutics Faces Delisting Notice
Ticker: CARM · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1485003
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Carisma Therapeutics got a delisting warning - big trouble ahead.
AI Summary
Carisma Therapeutics Inc. filed an 8-K on October 9, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Sesen Bio, Inc. and Eleven Biotherapeutics, Inc., is based in Philadelphia, PA.
Why It Matters
This filing indicates potential issues with Carisma Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation and stock viability.
Key Players & Entities
- Carisma Therapeutics Inc. (company) — Registrant
- Sesen Bio, Inc. (company) — Former Company Name
- Eleven Biotherapeutics, Inc. (company) — Former Company Name
- October 9, 2025 (date) — Date of Report
FAQ
What specific listing rule or standard has Carisma Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Carisma Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the expected timeline for Carisma Therapeutics to address the listing deficiency?
The filing does not provide a specific timeline for Carisma Therapeutics to address the listing deficiency.
Has Carisma Therapeutics taken any actions in response to this notice?
The filing does not detail any specific actions taken by Carisma Therapeutics in response to the delisting notice.
What are the potential consequences if Carisma Therapeutics cannot rectify the situation?
If Carisma Therapeutics cannot rectify the situation, the potential consequence is delisting from the stock exchange, which would significantly impact its stock's liquidity and value.
When was Carisma Therapeutics previously known by other names?
Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc. (name change date: 20180516) and Eleven Biotherapeutics, Inc. (name change date: 20100223).
Filing Stats: 1,106 words · 4 min read · ~4 pages · Grade level 15.9 · Accepted 2025-10-09 17:11:58
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share CARM The Nasdaq
Filing Documents
- tm2528458d1_8k.htm (8-K) — 28KB
- 0001104659-25-098404.txt ( ) — 191KB
- carm-20251009.xsd (EX-101.SCH) — 3KB
- carm-20251009_lab.xml (EX-101.LAB) — 33KB
- carm-20251009_pre.xml (EX-101.PRE) — 22KB
- tm2528458d1_8k_htm.xml (XML) — 4KB
01. Notice of Delisting or Failure to Satisfy a Continued
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 9, 2025, Carisma Therapeutics Inc. (the "Company") received a delisting determination letter (the "Determination Letter") from The Nasdaq Stock Market LLC ("Nasdaq"). The Determination Letter indicated that, as a result of the Company's previously disclosed noncompliance with the Nasdaq Listing Rules, the Company's common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") to complete the delisting of the Company's common stock from Nasdaq. The Company does not plan to appeal Nasdaq's determination. The Company has received approval of its application to list the Company's common stock on the OTCID market tier operated by The OTC Markets Group. The Company expects its common stock will commence trading on the OTCID market tier at the open of business on October 13, 2025 under the Company's current trading symbol "CARM." There is no guarantee, however, that a broker will continue to make a market in the Company's common stock or that trading of the common stock will continue on the OTCID market tier or otherwise or that the Company will continue to provide information sufficient to enable brokers to provide quotes for its common stock. The Company expects to continue to attempt to sell or otherwise dispose of or monetize its remaining assets and pursue an orderly wind down of its remaining operations. There can be no assurance that the Company will be able to identify and complete additional asset monetization transactions. It is unlikely that there will be a meaningful amount of cash available for distribution to stockholders in connection with a wind down of the Company's operations or a dissolution and liquidation
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARISMA THERAPEUTICS INC. By: /s/ Steven Kelly Date: October 9, 2025 Steven Kelly President and Chief Executive Officer